USP10 deubiquitinates and stabilizes CD44 leading to enhanced breast cancer cell proliferation, sternness and metastasis.

Sethi, Arppita; Mishra, Shivkant; Upadhyay, Vishal; Dubey, Parul; Siddiqui, Shumaila; Singh, Anil Kumar; Chowdhury, Sangita; Srivastava, Swati; Srivastava, Pragya; Sahoo, Prasannajit; Bhatt, Madan L. B.; Mishra, Anand; Trivedi, Arun Kumar

Despite extensive research, strategies to effectively combat breast cancer sternness and achieve a definitive cure remains elusive. CD44, a well-defined cancer stem cell (CSC) marker is reported to promote breast cancer tumorigenesis, metastasis, and chemoresis-tance. However, mechanisms leading to its enhanced expression and function is poorly understood. Here, we demonstrate that USP10 positively regulates CD44 protein levels and its downstream actions. While USP10 depletion prominently down-regulates CD44 protein levels and functions, its overexpression significantly enhances CD44 protein levels, leading to enhanced cluster tumor cell formation, stemness, and metastasis in breast cancer cells both in vitro and ex vivo in primary human breast tumor cells. USP10 interacts with CD44 and stabilizes it through deubiquitination both in breast cancer cell lines and human breast cancer-derived primary tumor cells. Stabilized CD44 shows enhanced interaction with cytoskeleton proteins Ezrin/Radixin/Moesin and potently activates PDGFRp/STAT3 signaling which are involved in promoting CSC traits. Using USP10 stably expressing 4T1 cells, we further demonstrate that the USP10-CD44 axis potently promotes tumorigenicity in vivo in mice, while simultaneous depletion of CD44 in these cells renders them ineffective. In line with these findings, we further showed that inhibition of USP10 either through RNAi or the pharmacological inhibitor Spautin-1 significantly mitigated CD44 levels and its downstream function ex vivo in primary breast tumor cells. Finally, we demonstrated that primary breast tumor cells are more susceptible to chemotherapy when co-treated with USP10 inhibitor indicating that the USP10-CD44 axis could be an attractive therapeutic target in combination with chemotherapy in CD44 expressing breast cancers.

METASTATIC breast cancer; CANCER cell proliferation; CANCER stem cells; CD44 antigen; EZRIN; BREAST

Biochemical Journal, 2024, Vol 481, Issue 24, p1877

0264-6021

Academic Journal

10.1042/BCJ20240611